| London Stock Exchange: TAIH
Taihua Plc engages in the development, production, and distribution of active pharmaceutical ingredients. It operates through the following segments: Paclitaxel, Homoharringtonine, and Traditional Chinese Medicine (TCM) Products.The Paclitaxel segment handles the manufacture and sale of a drug for the treatment of cancer of the ovaries, breast, certain types of lung cancer, and a cancer of the skin and mucous membranes. The Homoharringtonine segment produces and sells a drug prescribed for acute myeloid leukaemia and other cancers. The TCM Products segment manufactures Gengnianan, Duzhong Pingya, Zaoren Anshen Keli, Bunao Anshen, Jiangzi Jianfei, Dabaidu, and Runing Tablets. The company was founded on August 29, 2006 and is headquartered in Xi'an, China.